Stock listing

HVO Stock Price, News, Filings & Events — Hvivo Plc

Selected listing: HVO · LSE · GBX · GB

This page tracks Hvivo Plc's HVO:LSE listing on LSE in GBX for GB, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following HVO:LSE. HVO:LSE is the stock-level entry point for investors researching Hvivo Plc, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Hvivo Plc is a public company listed on the UK market under the ticker HVO, with a market capitalization of approximately £61.4 million. The company specializes in the development and commercialization of innovative solutions for infectious diseases. Hvivo focuses on advancing its proprietary technologies and conducting clinical trials to support its product pipeline.

HVO:LSEGBXGBUpdated August 21, 2026
Hvivo Plc logo
Ticker
HVO:LSE
Asset type
Stock
Market cap
$61.9M
Sector
Commercial Services
Industry
Miscellaneous Commercial Services
Exchange
LSE
Currency
GBX

Hvivo Plc HVO:LSE stock context

This page tracks Hvivo Plc's HVO:LSE listing on LSE in GBX for GB, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following HVO:LSE. HVO:LSE is the stock-level entry point for investors researching Hvivo Plc, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Hvivo Plc is a public company listed on the UK market under the ticker HVO, with a market capitalization of approximately £61.4 million. The company specializes in the development and commercialization of innovative solutions for infectious diseases. Hvivo focuses on advancing its proprietary technologies and conducting clinical trials to support its product pipeline.

Latest news from Hvivo Plc

All Hvivo Plc news →

Research Hvivo Plc

Alternate listings